Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Danish Biomonitor buys Neutekbio for €7 million

This article was originally published in Scrip

Executive Summary

Denmark's Biomonitor has bought Neutekbio, an Irish company focused on reporter gene technology, for more than €7 million. Neutekbio's largest stakeholder Growcorp, Ireland's first private company with an investment fund targeted specifically at the bioscience sector, will hold a 6% stake in Biomonitor. Galway-based Neutekbio has developed iLite, cell-based assays and kits that measure biological activity of cytokines such as interferons and neutralising antibodies to IFN and TNF-alpha antagonists. These assays are essential for monitoring drug profiles and the potential of immunogenicity of biopharmaceutical drugs throughout the entire development and postmarketing testing. Arsalan Kharazmi, Biomonitor CEO, said the acquisition would make Biomonitor the leading theranostic company. The Danish company, which has developed assays to monitor antibodies to several anti-inflammatory drugs, will continue the R&D and manufacturing operations in Ireland. Sunstone Capital, a Nordic early-stage venture capital investor, will provide funding for the acquisition. Growcorp has invested €3 million in Neutekbio since 2003, while Enterprise Equity and western Development Corporation contributed €1 million each.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts